• Novartis.com
  • Annual Reporting Suite
  • Investors
  • Coronavirus
  • Global
  • Novartis site directory
Novartis

Novartis in Society ESG Report 2020

  • Reporting Home
  • Annual Review
  • Novartis in Society ESG Report
  • At a glance
    • About this report
    • 2020 highlights
    • ESG management targets
    • Our response to COVID-19
    • Who we are
    • How we create value
    • Message from the Chairman
    • Message from the CEO
  • Our journey to build trust with society
    • Maintaining strong governance
    • Materiality and reporting
    • Engaging with stakeholders
    • Contributing to the Sustainable Development Goals
    • Valuing our impact
  • Strategic areas
    • Holding ourselves to high ethical standards
      • Creating a Code of Ethics
      • Safeguarding our company from risks
      • Strengthening internal assurance and advisory
      • Expanding the third-party risk management process
      • Upholding our commitment to human rights
      • Encouraging associates to speak up
      • Addressing legacy legal issues
    • Being part of the solution on pricing and access
      • Adapting medicines to address unmet needs
      • Developing effective affordability strategies
      • Integrated access programs & markets
      • Leaving no patient behind in sub-Saharan Africa
      • Patient assistance programs
      • Donations
      • Strengthening health systems
    • Addressing global health challenges
      • Joining forces to expand global access to COVID-19 solutions
      • Expanding the Novartis Africa Sickle Cell Disease program
      • Reimagining the fight against Chagas disease
      • Advancing a strong pipeline to help eliminate malaria
      • Accelerating leprosy elimination
      • Developing treatments for infectious and neglected tropical diseases
      • Taking a holistic approach to antimicrobial resistance
    • Being a responsible citizen
      • Helping ensure patient health and safety
      • Supporting patients and caregivers during COVID-19
      • Unleashing the power of our people
      • Enhancing environmental sustainability
      • Conducting animal research responsibly
  • Reporting and disclosures
    • Performance indicators 2020
    • Climate-related financial disclosures (TCFD)
    • Environmental, Social and Governance (ESG) Index
    • GRI content index and UNGC and SDG mapping
    • Sustainability Accounting Standards Board (SASB) index
    • Appendices
      • External initiatives and membership of associations
      • Measuring and valuing our impact
    • Independent Assurance Report

You are here:

  • Reporting Home
  • Novartis in Society ESG Report
  • Reporting and disclosures
  • Appendices
  • Measuring and valuing our impact

Appendix: measuring and valuing our impact

  • Direct GDP contribution method
  • Social impact of childhood pneumonia in Nigeria
  • White Paper on social risk in the supply chain
  • The social impact of the Tubeho Neza program in Rwanda
  • Meta Study social impact
    • Key Figures Comparison
    • Download center

Related links

  • Valuing our impact
  • Materiality and reporting
  • ESG management targets
External initiatives and membership of associationsprevious page
back to top
Independent Assurance Reportnext page
Services
  • Key figures comparison
  • Downloads
Subscribe to Novartis
Cookie Settings Novartis Site Directory

© 2021 Novartis AG

Novartis in Society ESG Report 2020
  • Terms of Use
  • Privacy Policy
  • Contact Us
  • Forward-looking statements
  • Site Map